Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

1.225 +0.025 (+2.08%)
Streaming Delayed Price Updated: 12:54 PM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,333,110
Open 1.210
Bid (Size) 1.220 (87)
Ask (Size) 1.230 (53)
Prev. Close 1.200
Today's Range 1.210 - 1.260
52wk Range 0.8621 - 3.780
Shares Outstanding 142,183,418
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has sent shockwaves through the biotechnology sector with its announcement on October 20, 2025, of a voluntary delisting of its American Depositary Shares... 
Via MarketMinute
Topics Initial Public Offering Regulatory Compliance Workforce
This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
 
Via Benzinga

Performance

YTD
-44.3%
-44.3%
1 Month
-2.0%
-2.0%
3 Month
-16.7%
-16.7%
6 Month
-22.0%
-22.0%
1 Year
-54.3%
-54.3%

More News

Read More
Allogene Therapeutics Announces Participation in Upcoming Investor Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics's Earnings Outlook
Via Benzinga
Allogene Q2 Cash Tops $300 Million
Via The Motley Fool
Allogene Narrows Loss in Fiscal Q2
Via The Motley Fool
Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Narrower-Than-Expected Q2 2025 Loss, Shares Rise Modestly
Via Chartmill
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For August 13, 2025
Via Benzinga
A Look at Allogene Therapeutics's Upcoming Earnings Report
Via Benzinga
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday
Via Benzinga
Allogene Resets Clinical Course After Patient Death In Lymphoma Study
Via Benzinga
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
From Allogene Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For May 13, 2025
Via Benzinga
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For March 13, 2025
Via Benzinga

Frequently Asked Questions

Is Allogene Therapeutics, Inc. - Common Stock publicly traded?
Yes, Allogene Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Allogene Therapeutics, Inc. - Common Stock trade on?
Allogene Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Allogene Therapeutics, Inc. - Common Stock?
The ticker symbol for Allogene Therapeutics, Inc. - Common Stock is ALLO on the Nasdaq Stock Market
What is the current price of Allogene Therapeutics, Inc. - Common Stock?
The current price of Allogene Therapeutics, Inc. - Common Stock is 1.225
When was Allogene Therapeutics, Inc. - Common Stock last traded?
The last trade of Allogene Therapeutics, Inc. - Common Stock was at 10/27/25 12:54 PM ET
What is the market capitalization of Allogene Therapeutics, Inc. - Common Stock?
The market capitalization of Allogene Therapeutics, Inc. - Common Stock is 174.17M
How many shares of Allogene Therapeutics, Inc. - Common Stock are outstanding?
Allogene Therapeutics, Inc. - Common Stock has 174M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.